AI assistant
Sending…
NovoCure Ltd — Director's Dealing 2022
Aug 4, 2022
31949_dirs_2022-08-04_cfdfeab8-92f5-4fac-9255-01d102bf197a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-08-03
Reporting Person: Benaim Ely (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-03 | Ordinary Shares | S | 563 | $71.09 | Disposed | 34068 | Direct |
| 2022-08-03 | Ordinary Shares | S | 5396 | $74 | Disposed | 28672 | Direct |
Footnotes
F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.
More from NovoCure Ltd
Proxy Solicitation & Information Statement
2026
May 21
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 24
Regulatory Filings
2026
Apr 9
Major Shareholding Notification
2026
Mar 26
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3